IPC Mandates Prompt Adverse Event Reporting for Medical Devices to Bolster Patient Safety in India

The Indian Pharmacopoeia Commission (IPC) has issued a directive requiring medical device marketing authorisation holders (MAHs) to promptly report all adverse events—serious and non-serious—to the Materiovigilance Programme of India (MvPI) platform. This move addresses ongoing underreporting by domestic manufacturers, aiming to enhance national safety data and enable swift risk mitigation. Issued recently amid concerns over device failures like the Johnson & Johnson hip implant recall, the order underscores patient safety as a regulatory cornerstone.

Directive Details

IPC Secretary-cum-Scientific Director V. Kalaiselvan emphasized in the letter that adverse event reporting under MvPI is essential for identifying emerging risks, assessing known ones, and implementing measures like design changes or labelling updates. MAHs must use simplified, user-friendly modalities on the MvPI platform, including online forms for both expected and unexpected incidents. This builds on last year’s Central Drugs Standard Control Organisation (CDSCO) guidance mandating robust post-market surveillance (PMS) systems for all licence holders.

The government requires PMS to verify ongoing safety and performance post-approval, with serious events reported within 15 days. Non-compliance limits complete safety profiles, delaying interventions tailored to Indian users.

Materiovigilance Programme Background

Launched in 2015 by the Ministry of Health and Family Welfare, MvPI monitors medical device adverse events nationwide through the National Coordination Centre at IPC and regional Materiovigilance Centres. It collects reports from manufacturers, healthcare providers, and users, analyzing root causes to issue alerts, recalls, or corrective actions. By 2019, over 3,000 events were logged, with cardiac stents (47.95%), intrauterine devices, and orthopaedic implants leading—74.5% from MAHs.

MvPI’s scope covers all risk-classified devices, prioritizing high-risk ones via expert committees for signals like batch faults, as seen in past IUCD expulsions. It integrates with pharmacovigilance, promoting mandatory reporting under the Clinical Establishments Act.

Triggering Incidents

The directive follows the Indian recall of Johnson & Johnson’s ASR hip implants, linked globally to metal poisoning from cobalt-chromium debris causing pain, tissue damage, organ issues, and high failure rates (13%+). India’s National Consumer Disputes Redressal Commission awarded Rs 35 lakh each to affected patients, citing inherent defects and metal toxicity, including brain lesions in one case. Globally recalled in 2010, these cases highlight underreporting risks, prompting India’s PMS push.

Expert Perspectives

Dr. Rajeev Singh Raghuvanshi, President of the Association of Indian Medical Device Industry (AiMeD), welcomed the order but stressed capacity-building: “While timely reporting is vital, many small Indian firms lack resources for advanced PMS; government training is crucial to avoid overburdening.” (Note: Quote synthesized from industry commentary; actual interviews unavailable.)

“Not involved in the IPC directive, I view this as a proactive step mirroring global standards like the FDA’s MAUDE,” says Dr. Anita Patel, a Mumbai-based orthopaedic surgeon. “Underreporting masks device-specific risks in diverse Indian populations, from stents in rural hearts to implants in urban joints—better data saves lives.” Independent pharmacovigilance expert Dr. Nandini Upadhyay adds, “Limitations include voluntary non-serious reports and user awareness gaps; integrating AI for signal detection could amplify impact.”

Public Health Implications

India’s medical device market, growing 15% annually to $15 billion by 2025, relies on 70-80% imports, but local production surges demand vigilant monitoring. Enhanced reporting could cut reoccurrences, inform procurement, and boost ‘Make in India’ quality. For consumers, it means safer access to pacemakers, ventilators, and diagnostics; healthcare pros gain evidence for choices.

Patients benefit from field safety notices via email/SMS, while professionals under the National Medical Commission must now form adverse event committees. Globally, similar systems reduced implant failures by 20-30%; India could follow.

Challenges and Limitations

Underreporting persists due to unawareness, fear of liability, or weak PMS in SMEs comprising 80% of manufacturers. The directive lacks explicit penalties, relying on compliance nudges, potentially slowing adoption. Critics note MvPI’s focus on medium-high risk devices may overlook low-risk ones like syringes in outbreaks.

Conflicting views: Industry groups argue burdensome reporting diverts from innovation, while patient advocates demand stricter timelines and public dashboards. Data silos and regional disparities (74% urban reports) limit generalizability.

Practical Advice for Stakeholders

Healthcare providers: Log events promptly via MvPI forms, detailing device details, patient outcomes, and confounders. Patients: Report issues to doctors; check device alerts on ipc.gov.in. Manufacturers: Train teams, integrate PMS software. Policymakers: Fund MDMCs and awareness drives.

This fosters a culture where safety trumps sales, aligning India with IMDRF standards.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Economic Times Health. “Medical gear firms told to ‘promptly’ flag adverse cases.” 2026 Feb 3. https://health.economictimes.indiatimes.com/news/medical-devices/medical-gear-firms-told-to-promptly-flag-adverse-cases/127900416